Nothing Special   »   [go: up one dir, main page]

BRPI0716498A2 - Genes e polipeptídeos relacionados a cânceres de mama - Google Patents

Genes e polipeptídeos relacionados a cânceres de mama

Info

Publication number
BRPI0716498A2
BRPI0716498A2 BRPI0716498-0A2A BRPI0716498A BRPI0716498A2 BR PI0716498 A2 BRPI0716498 A2 BR PI0716498A2 BR PI0716498 A BRPI0716498 A BR PI0716498A BR PI0716498 A2 BRPI0716498 A2 BR PI0716498A2
Authority
BR
Brazil
Prior art keywords
polypeptides
breast cancer
related genes
genes
breast
Prior art date
Application number
BRPI0716498-0A2A
Other languages
English (en)
Inventor
Yusuke Nakamura
Toyomasa Katagiri
Shuichi Nakatsuru
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of BRPI0716498A2 publication Critical patent/BRPI0716498A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
BRPI0716498-0A2A 2006-08-10 2007-08-10 Genes e polipeptídeos relacionados a cânceres de mama BRPI0716498A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83742806P 2006-08-10 2006-08-10
US84025006P 2006-08-25 2006-08-25
US91502207P 2007-04-30 2007-04-30
PCT/JP2007/065992 WO2008018642A2 (en) 2006-08-10 2007-08-10 Genes and polypeptides relating to breast cancers

Publications (1)

Publication Number Publication Date
BRPI0716498A2 true BRPI0716498A2 (pt) 2015-01-27

Family

ID=38627000

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0716498-0A2A BRPI0716498A2 (pt) 2006-08-10 2007-08-10 Genes e polipeptídeos relacionados a cânceres de mama

Country Status (8)

Country Link
US (2) US8673548B2 (pt)
EP (1) EP2057187B1 (pt)
JP (1) JP5339291B2 (pt)
KR (1) KR20090064378A (pt)
BR (1) BRPI0716498A2 (pt)
CA (1) CA2660438A1 (pt)
SG (1) SG174071A1 (pt)
WO (1) WO2008018642A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1668354A2 (en) 2003-09-24 2006-06-14 Oncotherapy Science, Inc. Method of diagnosing breast cancer
AU2006275753B2 (en) 2005-07-29 2012-01-12 Targeted Growth, Inc. Dominant negative mutant KRP protein protection of active cyclin-CDK complex inhibition by wild-type KRP
JP5514453B2 (ja) * 2008-03-04 2014-06-04 株式会社キノファーマ 発光タンパク質を用いたリン酸化酵素阻害物質のスクリーニング方法
EP2275567A1 (en) * 2009-07-15 2011-01-19 Rheinische Friedrich-Wilhelms-Universität Bonn Nucleic acid expression construct and its use as a cell proliferation marker
EP2542155B1 (en) * 2010-03-01 2015-11-04 TAU Therapeutics LLC Method for imaging a disease
WO2012065166A2 (en) * 2010-11-12 2012-05-18 Targeted Growth, Inc. Dominant negative mutant kip-related proteins (krp) in zea mays and methods of their use
WO2012142116A2 (en) 2011-04-11 2012-10-18 Targeted Growth, Inc. Identification and use of krp mutants in wheat
RU2017129844A (ru) 2011-04-11 2019-02-06 Таргетед Гроус, Инк. Идентификация и применение мутантных krp у растений
EP2738255B1 (en) * 2011-07-29 2016-11-23 Tokushima University Erap1-derived peptide and use thereof
DK3296317T3 (da) * 2011-10-28 2020-02-24 Oncotherapy Science Inc Topk-peptider og vacciner, der indbefatter disse
CN104126010B (zh) * 2011-12-16 2021-04-06 国立大学法人东京医科齿科大学 嵌合的双链核酸
GB201121924D0 (en) * 2011-12-20 2012-02-01 Fahy Gurteen Labs Ltd Detection of breast cancer
WO2016011143A1 (en) * 2014-07-15 2016-01-21 Temple University Of The Commonwealth System Of Higher Education Stabilized peptide fragments from redoxin proteins as cancer biomarkers
CN104497147B (zh) * 2014-12-23 2018-07-03 四川大学 一种双受体识别的串联型穿膜肽修饰的肿瘤靶向纳米递药系统
WO2017126461A1 (ja) 2016-01-19 2017-07-27 国立大学法人徳島大学 がん治療用ペプチド及びそれを含む医薬組成物
US20210206818A1 (en) 2016-01-22 2021-07-08 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
KR102658844B1 (ko) 2017-07-19 2024-04-17 토쿠시마 대학 펩티드 유도체 및 약학적 조성물
CN114773480A (zh) * 2022-06-07 2022-07-22 厦门大学附属翔安医院 一种抗topk第32位丝氨酸残基磷酸化的抗体
CN116082447A (zh) * 2022-09-09 2023-05-09 湖南大学 一种多肽及其制备方法
CN117757789A (zh) * 2022-09-26 2024-03-26 领星生物科技（上海）有限公司 用于抑制肿瘤生长的siRNA及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656698B1 (en) * 1999-06-30 2003-12-02 Millennium Pharmaceuticals, Inc. 12832, a novel human kinase-like molecule and uses thereof
EP1074617A3 (en) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2002029104A2 (en) 2000-10-03 2002-04-11 Glaxo Group Limited Tumor marker and methods of use
US7229960B2 (en) * 2000-11-03 2007-06-12 University Of Vermont And State Agricultural College Methods and compositions for inhibiting GRB7
AU2002246502A1 (en) 2000-11-17 2002-08-06 Hyseq, Inc. Nucleic acids and polypeptides
WO2002059271A2 (en) 2001-01-25 2002-08-01 Gene Logic, Inc. Gene expression profiles in breast tissue
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003043568A2 (en) 2001-11-15 2003-05-30 The Regents Of The University Of California Compositions and methods for the suppression of mammary epithelial cell proliferation
US6833247B2 (en) * 2002-05-14 2004-12-21 Origene Technologies, Inc. Regulated prostate cancer genes
US20060241015A1 (en) 2002-01-25 2006-10-26 Zairen Sun Cancer genes
WO2003070889A2 (en) 2002-02-19 2003-08-28 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
CA2495389A1 (en) * 2002-08-19 2004-02-26 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2500982A1 (en) 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Method for diagnosing testicular seminomas
US6971476B2 (en) * 2003-09-05 2005-12-06 D B Industries, Inc. Safety harness
EP1668354A2 (en) 2003-09-24 2006-06-14 Oncotherapy Science, Inc. Method of diagnosing breast cancer
US7998695B2 (en) * 2005-02-10 2011-08-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
WO2006110593A2 (en) 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
EP2311985A1 (en) 2005-07-27 2011-04-20 Oncotherapy Science, Inc. Sirna for treating esophageal cancer
EP1907580A2 (en) 2005-07-28 2008-04-09 Oncotherapy Science, Inc. Method for diagnosing and treating renal cell carcinoma
CN101861321B (zh) * 2007-10-11 2013-02-06 阿斯利康(瑞典)有限公司 作为蛋白激酶b抑制剂的吡咯并[2,3-d]嘧啶衍生物
AU2009310310A1 (en) * 2008-10-30 2010-05-06 Oncotherapy Science, Inc. 7-Hydroxy-benzoimidazole-4-yl-methanone Derivatives and PBK inhibitors containing the same

Also Published As

Publication number Publication date
WO2008018642A3 (en) 2008-04-03
CA2660438A1 (en) 2008-02-14
WO2008018642A2 (en) 2008-02-14
EP2057187A2 (en) 2009-05-13
US9187557B2 (en) 2015-11-17
US20140228238A1 (en) 2014-08-14
EP2057187B1 (en) 2016-12-28
US20110135647A1 (en) 2011-06-09
KR20090064378A (ko) 2009-06-18
JP2010500003A (ja) 2010-01-07
JP5339291B2 (ja) 2013-11-13
US8673548B2 (en) 2014-03-18
SG174071A1 (en) 2011-09-29
EP2444417A1 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
BRPI0716498A2 (pt) Genes e polipeptídeos relacionados a cânceres de mama
HK1108273A2 (en) Simultaneous sensing arrangement
IL197573A0 (en) Directional use
DK2115472T3 (da) Cancerbiomarkører
GB0813682D0 (en) Proximity sensor
GB0610741D0 (en) Material detection
GB0715653D0 (en) Garments
BRPI0720226A2 (pt) Genes marcadores selecionáveis
GB0620620D0 (en) Pervasive sensing
EP2050881A4 (en) ARROW
EP2094218A4 (en) SENSOR
GB0713413D0 (en) Phased based sensing
GB0619243D0 (en) Activation sensing
PL2001815T3 (pl) Materiał typu cementu
GB0616290D0 (en) Material
GB2460582B (en) Proximity sensing
EP2180205A4 (en) ENERGY ABSORPTION MATERIAL
GB0623160D0 (en) Biomolecules
GB0618429D0 (en) Cancer test
GB0603248D0 (en) Portable object sensing assembly
EP2071315A4 (en) MEASURING DEVICE
EP2071316A4 (en) DETECTION DEVICE
GB2428342B (en) Proximity sensing
GB0610720D0 (en) Material detection
GB0608020D0 (en) Sheeting

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.